Strong associations exist between drug exposure and patient outcomes for many antimicrobials. Therapeutic drug monitoring (TDM) is an obvious method to apply to ensure more patients achieve effective drug concentrations and should be considered standard-of-care for most antimicrobials. However, there is still uncertainty and inconsistency of practice about which patients would most benefit from TDM, which antimicrobial concentration targets should be used and what methods are feasible and could be applied to effectively change doses. In this workshop, we address these issues as they relate to antibacterials, antifungals and antimycobacterials. We also present new technological advances that improve the feasibility and accuracy of antimicrobial TDM, and specific considerations for key settings including paediatrics and outpatients (and critically ill patients of course!) as well as the place of dosing software. Watch our recordings to hear from leading practitioners and scientists in this area!
Antimicrobial Therapeutic Drug Monitoring Workshop
Wednesday, 11 November 2020, Virtual Event, delivered by zoom
| Time | Topic | Speaker | |
|---|---|---|---|
| Session 1: Dose Optimisation and PK PD Chair Prof Jason Roberts | |||
| 0900-0905 | Welcome | Prof Jason Roberts (Brisbane) | |
| 0905-0925 | The need for antimicrobial dose optimisation | Prof Jason Roberts (Brisbane) | |
| 0925-0945 | Different approaches to antimicrobial dose optimisation | Mr Paul Williams (Sunshine Coast) | |
| 0945-1005 | Antibacterial pharmacokinetic-pharmacodynamic targets | Dr Kathryn Daveson (Canberra) | |
| 1005-1025 | Antifungal pharmacokinetic-pharmacodynamic targets | Dr Hafiz Abdul-Aziz (Brisbane) | |
| 1025-1045 | Antimycobacterial pharmacokinetic-pharmacodynamic targets | Dr Andrew Burke (Brisbane) | |
| 1045-1105 | Morning Tea (20min) | ||
| Session 2: Therapeutic Drug Monitoring Concepts | Chair Dr Suzanne Parker (Brisbane) | ||
| 1105-1125 | Principles of therapeutic drug monitoring (TDM) | A/Prof Darren Roberts (Sydney) | |
| 1125-1145 | Outcome and cost-effectiveness data supporting antimicrobial TDM | Dr Gloria Wong (Brisbane) | |
| 1145-1205 | Considerations for TDM in paediatrics | Dr Amanda Gwee (Melbourne) | |
| 1205-1225 | Antimicrobial susceptibility testing considerations for TDM | Prof John Turnidge (Adelaide) | |
| 1225-1245 | Study design considerations to quantify the clinical value of TDM | Prof Jan-Willem Alffenaar (Sydney) | |
| 1245-1345 | Lunch (60min) | ||
| Session 3: Dosing Software | Chair Dr Andrew Burke (Brisbane) | ||
| 1345-1405 | Use of TDM in the outpatient setting | Dr Kate McCarthy (Brisbane) | |
| 1405-1425 | Technological advances to revolutionise TDM: Sampling and Bioanalytics | Dr Suzanne Parker (Brisbane) | |
| 1425-1445 | Technological advances to revolutionise TDM: Dosing software | Mr Gene Chai (Brisbane) | |
| 1445-1515 | IDS-ODS Dosing Software | Dr Andras Farkas (New York) | |
| 1515-1545 | Afternoon tea (30min) | ||
| Session 4: Dosing Software Practical Applications | Chair Prof Jason Roberts (Brisbane) | ||
| 1545-1630 | IDS-ODS case studies: vancomycin and meropenem | Mr Paul Williams and Mr Gene Chai (Brisbane) | |
| 1630-1640 | Close | Prof Jason Roberts | |
| 1640-1800 | Dinner break (80min) | ||
| Session 5: European Perspectives | Chair Dr Claire Roger (Nîmes) | ||
| AEST | CET | Topic | Speaker |
| 1800-1805 | 0900-0905 | Welcome from Nîmes | Dr Claire Roger (Nîmes) |
| 1805-1825 | 0905-0925 | International Guidelines for antimicrobial TDM | Dr Jan De Waele (Belgium) |
| 1830-1850 | 0930-0950 | Dosing software for optimising therapy | Dr Sylvain Goutelle |
| 1855-1915 | 0955-1015 | Dosing challenges in obese patients | Prof Bernard Allaouchiche |
| 1920-1940 | 1020-1040 | Vancomycin use in Europe | Prof Marc Leone |
| 1945-2005 | 1045-1105 | TDM of linezolid and daptomycin | Dr Sonia Luque |
| 2010-2030 | 1110-1130 | Close | Dr Claire Roger |
View more videos on the CRE REDUCE YouTube channel.
